BHS Biotechnology is a newly formed company, wholly owned by BioHybrid Solutions Holdings, Inc. (BHSH). All BHSH companies are endeavoring under the BioHybrid Solutions (BHS) banner. BHS’s vision is to deliver safe and effective biologic drugs to patients everywhere. Our mission is to harness science for the precise design and development of breakthrough biologic medicines. Our systematic in silico and in vitro process exerts ImmunoControl™ through our EpitopeSilencing™ process, improving pharmacokinetics and increasing the half-life of NanoArmored™ biologic therapeutics while maintaining activity. In addition, the ImmunoControlTM platform can be used for EpitopeTargeting™ and EpitopeAccentuation™ allowing for the discovery of new drugs against secondary, silent epitopes. Visit us at www.biohybridsolutions.com to learn more.